Chemotherapy-induced neuropathic pain

@article{Farquharsmith2011ChemotherapyinducedNP,
  title={Chemotherapy-induced neuropathic pain},
  author={Paul Farquhar-smith},
  journal={Current Opinion in Supportive and Palliative Care},
  year={2011},
  volume={5},
  pages={1–7}
}
  • P. Farquhar-smith
  • Published 1 March 2011
  • Medicine
  • Current Opinion in Supportive and Palliative Care
Purpose of reviewTo discuss the importance, clinical features, possible pathology and treatments of chemotherapy-induced neuropathic pain. Newer biological agents such as bortezomib will be considered in greater detail. Recent findingsChemotherapy-induced peripheral neuropathy (CIPN) is a frequent complication of common anticancer therapies. It may lead to treatment compromise, significantly adds to the symptom burden and interferes with quality of life of cancer survivors. Recent… 
View on Wolters Kluwer
ncbi.nlm.nih.gov
102 Citations
Highly Influential Citations
11
Background Citations
45
Methods Citations
2
Results Citations
2

102 Citations

Citation Type

Citation Type

Chemotherapy induced peripheral neuropathic pain
  • H. Park
  • Medicine
    Korean journal of anesthesiology
  • 2014
TLDR
Although tricyclic antidepressants, gabapentin, and a topical gel containing baclofen, amitriptyline HCL, and ketamine showed inconclusive results in CIPN trials, these agents are currently considered the best options for CIPn treatment.
Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN)
TLDR
The pathobiology of CIPN is complex as cancer chemotherapy treatment regimens frequently involve drug combinations and there are also subtle differences in the pathobiological consequences of commonly used cancer chemotherapy drugs on peripheral nerves.
Brief review: Chemotherapy-induced painful peripheral neuropathy (CIPPN): current status and future directions
TLDR
Mechanisms, clinical signs and symptoms, diagnosis, treatment options, and prognosis for patients who develop CIPPN are reviewed and the innovative use of several non-traditional categories of drugs seems promising in the management of this complex phenomenon.
Neuropathic cancer pain: What we are dealing with? How to manage it?
TLDR
The purpose of this review is to discuss neuropathic pain and NCP in detail, the relevance of this topic, clinical features, possible pathology, and treatments of NCP.
Basic science and clinical management of painful and non-painful chemotherapy-related neuropathy.
Chemotherapy-induced peripheral neuropathic pain
TLDR
The objective of the article is to discuss the nature of the peripheral neuropathy associated with chemotherapeutic agents, their clinical features, evaluation, and subsequent clinical management.
Pain in chemotherapy-induced neuropathy – More than neuropathic?
Clinical and biochemical markers in CIPN: A reappraisal.
Prevalence and aetiology of neuropathic pain in cancer patients: A systematic review
Chemotherapy-Induced Neuropathic Pain
TLDR
Drug Treatment for Chemotherapy-Induced Neuropathic Pain: Amitriptyline as an Example Eija Kalso Experimental Design and Analysis of Drug Combinations Applicable to Chemotherapy’s induced neuropathic pain.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 78 REFERENCES
[Chemotherapy-induced peripheral neuropathy: an unresolved issue].
Patient perceptions associated with chemotherapy-induced peripheral neuropathy.
  • C. Tofthagen
  • Medicine, Psychology
    Clinical journal of oncology nursing
  • 2010
TLDR
The results of this study emphasize the importance of ongoing assessment and communication with patients about their experiences with peripheral neuropathies and knowledge of what patients with CIPN experience will guide nurses in suggesting interventions to promote safety and help alleviate symptoms.
Venlafaxine for treatment of chemotherapy-induced neuropathic pain
TLDR
Venlafaxine seems to effectively improve chemotherapy induced neuropathic pain with moderate manageable toxicity, and this observation warrants further study for comparison with other antidepressants.
Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel.
  • C. Reyes-Gibby, P. Morrow
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
Empirical evidence is provided on the importance CIPN as a risk factor for NP in breast cancer patients and how it is associated with cummulative dose of paclitaxel, and comorbid conditions such as diabetes and osteoarthritis.
Quantitative sensory findings in patients with bortezomib-induced pain.
Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies
TLDR
A future avenue of investigation includes the identification of patients at higher risk for the development of peripheral neuropathy based on their genotype, to enable us to devise prevention strategies prior to the onset of this potentially debilitating complication.
Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.
Chemotherapy‐induced neuropathy
Abstract  Neurotoxic side effects of cancer therapy are second in frequency to hematological toxicity. Unlike hematological side effects that can be treated with hematopoietic growth factors,…
Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study.
TLDR
Gabapentin monotherapy seems to be well tolerated and useful for the management of chemotherapy-induced neuropathic pain.
Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms.
...
1
2
3
4
5
...